Novo Nordisk (NYSE:NVO) announced today that its acquisition of Dicerna Pharmaceuticals (NSDQ:DRNA) has been completed.
Completion of the acquisition, initially announced on Nov. 18, 2021, follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna at 11:59 p.m. ET on Dec. 24, 2021.
Get the full story at our sister site, Drug Delivery Business News.